TransMedics price target raised to $92 from $90 at Oppenheimer

Oppenheimer raised the firm’s price target on TransMedics to $92 from $90 and keeps an Outperform rating on the shares. TransMedics reported blowout Q2 revenues of $52.5M, handily beating Street estimates, due to continued strong NOP adoption, increased supply capacity and strength across all organs, the analyst tells investors in a research note.